Posted inNews and Updates
Zydus Gets Green Light for Phase III Sickle Cell Drug Trial
Zydus Lifesciences, in partnership with ICMR, begins Phase III trials for Desidustat to treat Sickle Cell Disease. Learn about this potential new therapy.
Posted inNews and Updates
India Pharma Growth Outpaces US Tariff Adjustments
Discover how India’s pharmaceutical sector is maintaining steady growth and building global resilience despite evolving US trade and tariff regulations.
Posted inNews and Updates
AstraZeneca Secures EU Approval for New Breast Cancer Drug
AstraZeneca gains EU authorization for a new breast cancer therapy. Learn how this targeted ADC drug is set to transform treatment for HER2-low patients.
Posted inNews and Updates
Venus Medtech Completes Enrollment for Venus-PowerX Trial
Venus Medtech has finished enrolling patients in its PREVAILS trial for the Venus-PowerX TAVR system, a major step toward advancing structural heart care.
Posted inNews and Updates
FDA Reviews Encaleret for Rare Hypocalcemia Treatment
The FDA has accepted BridgeBio’s NDA for encaleret, a potential first-in-class treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Posted inNews and Updates
LB Pharmaceuticals Speeds Up NOVA-2 Schizophrenia Trial
LB Pharmaceuticals accelerates the NOVA-2 schizophrenia trial. Discover how this promising drug could redefine treatment standards for psychiatric care.
Posted inNews and Updates
Mastering Phase 1 iPSC Trials: Key Lessons for Success
Discover how a critical two-week observational window in Phase 1 iPSC trials is redefining clinical design and speeding up the path to regulatory approval.
Posted inNews and Updates
India’s Pharma Market Hits Two-Year Growth Peak Amid Shift
India’s pharma sector hits a two-year growth high as firms prepare for potential U.S. tariff shifts. Read how key manufacturers are navigating global trends.
Posted inNews and Updates
EU Approves Camizestrant for Advanced Breast Cancer
The EU has approved Camizestrant as a first-line treatment for ER-positive, HER2-negative advanced breast cancer when combined with a CDK4/6 inhibitor.
Posted inNews and Updates
Kalshi Launches Prediction Markets for FDA Drug Decisions
Kalshi is now allowing prediction markets for FDA drug approvals and clinical trial outcomes. Discover how this shift impacts biotech and market forecasting.